Inmune Bio Inc (INMB)

$2.01 +0.05 (2.55%)
Market Cap 52.11M
Revenue (ttm) 10,000.00
Net Income (ttm) -42.08M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -420,800.03%
Debt to Equity Ratio 0.00
Volume 256,800
Avg Vol 1,213,526
Day's Range N/A - N/A
Shares Out 26.59M
Stochastic %K 26%
Beta 1.04
Analysts Sell
Price Target $9.65

Company Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of b...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 964 3720
Address:
225 NE Mizner Blvd., Suite 640, Boca Raton, United States
NachoBusiness
NachoBusiness Oct. 8 at 1:53 PM
$INMB range 1.93-2.04 updated as of now
0 · Reply
NachoBusiness
NachoBusiness Oct. 8 at 1:24 PM
$INMB range 1.81 - 2.11 today
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 7 at 2:05 PM
12/19. $INMB Open interest 2,150 at 17.50 Stock price is currently 2.04 Something’s coming
0 · Reply
NachoBusiness
NachoBusiness Oct. 7 at 2:05 PM
$INMB range has now lowered to 1.94
0 · Reply
NachoBusiness
NachoBusiness Oct. 7 at 1:56 PM
$INMB 1.98-2.09 range today
0 · Reply
Pkinla
Pkinla Oct. 6 at 4:30 PM
$INMB Trio Wins Nobel Prize in Medicine for Discoveries on Immune System. Xpro already built on this science !
0 · Reply
NachoBusiness
NachoBusiness Oct. 6 at 2:37 PM
$INMB 2.06 - 2.15 range today.
0 · Reply
CcBuyer
CcBuyer Oct. 6 at 1:17 AM
$INMB New release with manuscript submission on XPro in Peer reviewed journal AND a Shareholder meeting….
0 · Reply
CcBuyer
CcBuyer Oct. 6 at 1:16 AM
$INMB
0 · Reply
scannerKing
scannerKing Oct. 5 at 7:51 AM
$INMB Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
Latest News on INMB
INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:23 PM EDT - 2 months ago

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Aug 4, 2025, 8:00 AM EDT - 2 months ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 31, 2025, 7:00 AM EDT - 2 months ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jul 29, 2025, 7:00 AM EDT - 2 months ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

Jul 4, 2025, 11:48 PM EDT - 3 months ago

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Jul 4, 2025, 9:20 AM EDT - 3 months ago

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 4:05 PM EDT - 3 months ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

Jun 30, 2025, 11:52 AM EDT - 3 months ago

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:36 AM EDT - 3 months ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 30, 2025, 7:30 AM EDT - 3 months ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

INmune Bio: Finding Pay Dirt In Alzheimer's?

Jun 27, 2025, 4:50 PM EDT - 3 months ago

INmune Bio: Finding Pay Dirt In Alzheimer's?

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 27, 2025, 12:16 PM EDT - 3 months ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

Jun 27, 2025, 10:38 AM EDT - 3 months ago

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

Jun 26, 2025, 4:00 PM EDT - 3 months ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity

Jun 16, 2025, 11:29 AM EDT - 4 months ago

INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity

INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

May 15, 2025, 5:28 PM EDT - 5 months ago

INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript

May 10, 2025, 3:57 AM EDT - 5 months ago

INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:10 PM EDT - 5 months ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

May 5, 2025, 7:00 AM EDT - 5 months ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Apr 14, 2025, 8:00 AM EDT - 6 months ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:15 PM EDT - 6 months ago

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Mar 27, 2025, 4:05 PM EDT - 6 months ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

Mar 21, 2025, 1:15 PM EDT - 7 months ago

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

PNW PRI

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

Mar 18, 2025, 4:31 PM EDT - 7 months ago

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 12, 2025, 7:00 AM EST - 8 months ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Feb 10, 2025, 7:00 AM EST - 8 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Jan 2, 2025, 8:52 AM EST - 9 months ago

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Dec 30, 2024, 3:20 PM EST - 10 months ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Dec 4, 2024, 9:00 AM EST - 11 months ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 8:09 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 31, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 28, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 3:03 PM EDT - 1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 24, 2024, 9:30 AM EDT - 1 year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Oct 11, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 30, 2024, 5:04 AM EDT - 1 year ago

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 26, 2024, 8:00 AM EDT - 1 year ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 17, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 13, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces $13.0 Million Registered Direct Offering

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Sep 3, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 11:50 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Aug 1, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 29, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Jul 23, 2024, 8:45 AM EDT - 1 year ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

Jul 8, 2024, 6:12 AM EDT - 1 year ago

INmune Bio: Promising Phase 2 Trials For Alzheimer's Drug XPro

INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

Jul 5, 2024, 9:57 AM EDT - 1 year ago

INmune Bio: Still A Bargain If Their Alzheimer's Program Reaches Its Inflection

INmune Bio Inc. to Join Russell 3000® Index

May 30, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Join Russell 3000® Index

INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript

May 11, 2024, 8:58 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q1 2024 Earnings Call Transcript

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

May 9, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

NachoBusiness
NachoBusiness Oct. 8 at 1:53 PM
$INMB range 1.93-2.04 updated as of now
0 · Reply
NachoBusiness
NachoBusiness Oct. 8 at 1:24 PM
$INMB range 1.81 - 2.11 today
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 7 at 2:05 PM
12/19. $INMB Open interest 2,150 at 17.50 Stock price is currently 2.04 Something’s coming
0 · Reply
NachoBusiness
NachoBusiness Oct. 7 at 2:05 PM
$INMB range has now lowered to 1.94
0 · Reply
NachoBusiness
NachoBusiness Oct. 7 at 1:56 PM
$INMB 1.98-2.09 range today
0 · Reply
Pkinla
Pkinla Oct. 6 at 4:30 PM
$INMB Trio Wins Nobel Prize in Medicine for Discoveries on Immune System. Xpro already built on this science !
0 · Reply
NachoBusiness
NachoBusiness Oct. 6 at 2:37 PM
$INMB 2.06 - 2.15 range today.
0 · Reply
CcBuyer
CcBuyer Oct. 6 at 1:17 AM
$INMB New release with manuscript submission on XPro in Peer reviewed journal AND a Shareholder meeting….
0 · Reply
CcBuyer
CcBuyer Oct. 6 at 1:16 AM
$INMB
0 · Reply
scannerKing
scannerKing Oct. 5 at 7:51 AM
$INMB Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 11:45 AM
$RADX Do your due diligence https://scr.zacks.com/news/news-details/2025/RADX-RAD101-Imaging-Recurring-Brain-Metastases-article/default.aspx $PYXS $IMNM $ADCT $INMB
0 · Reply
NachoBusiness
NachoBusiness Oct. 3 at 12:04 PM
$INMB looks like they will be shorting this heavy today or news is about to drop. Volume PM is significant
1 · Reply
NachoBusiness
NachoBusiness Oct. 2 at 4:21 PM
$INMB Level 2 tells us daily the range we will be in.. GSCO broker has us 2.08-2.16 range It was 2.08-2.22 earlier but volume trailed off
0 · Reply
CalculatedSwing
CalculatedSwing Oct. 1 at 4:02 PM
$BIVI 🚀 $BIVI heating up ahead of Oct 8 investor webinar—analysts flash Strong Buy with $16 PT from $1.90! Neuro pipeline crushing it on Alzheimer's & Parkinson's breakthroughs. Newbies, this is prime time to go all in for massive gains! 🌕 Tagging the neuro squad: $SAVA $ANVS $INMB $PRTA #Biotech #Neuro #AllIn
0 · Reply
BigSwingMoe
BigSwingMoe Sep. 30 at 1:41 PM
$INMB $BULL $OMEX $SPRC potential big movers... and gap ups coming
0 · Reply
Omaroio
Omaroio Sep. 30 at 12:15 PM
$INMB
0 · Reply
bioinvestorrr
bioinvestorrr Sep. 29 at 6:24 PM
$INMB interesting
0 · Reply
Omaroio
Omaroio Sep. 29 at 5:16 PM
$INMB
0 · Reply
Omaroio
Omaroio Sep. 29 at 2:36 PM
$INMB
0 · Reply
whitephosphorus970
whitephosphorus970 Sep. 29 at 12:26 PM
$INMB https://x.com/i/grok/share/fFFV7wCoRAuc3o2x0EqELLNne
0 · Reply
DARKP00L
DARKP00L Sep. 29 at 12:18 PM
$INMB 08:03 on Sep. 29 2025 INmune Bio Submits Manuscript Detailing Results Of Phase 2 MINDFuL Trial To Nature Portfolio Journal, npj Dementia #tradeideas
0 · Reply
DonCorleone77
DonCorleone77 Sep. 29 at 12:08 PM
$INMB "INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer's Disease to npj Dementia, a Nature Portfolio Journal" https://finviz.com/news/178162/inmune-bio-announces-submission-of-phase-2-mindful-trial-results-in-alzheimers-disease-to-npj-dementia-a-nature-portfolio-journal
0 · Reply